Protagonist Therapeutics, Inc. (NASDAQ: PTGX) Stock Competitors & Peer Comparison
See PTGX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PTGX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PTGX | $140.06 | +0.63% | 9B | 135.98 | $1.03 | N/A |
| VRTX | $504.73 | -0.40% | 128.1B | 26.52 | $19.03 | N/A |
| REGN | $735.20 | +0.05% | 75.7B | 16.11 | $45.63 | +0.50% |
| MRNA | $190.01 | +0.57% | 75.4B | -23.31 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $919.21 | -1.79% | 57.2B | 33.14 | $27.73 | N/A |
| RVMDW | $11.41 | -1.64% | 45.2B | -1.31 | -$8.82 | N/A |
| RVMD | $206.64 | +0.36% | 43.9B | -23.43 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $358.07 | -0.20% | 38.3B | 63.04 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
PTGX vs VRTX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, VRTX has a market cap of 128.1B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while VRTX trades at $504.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas VRTX's P/E ratio is 26.52. In terms of profitability, PTGX's ROE is +0.12%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, PTGX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
PTGX vs REGN Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, REGN has a market cap of 75.7B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while REGN trades at $735.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas REGN's P/E ratio is 16.11. In terms of profitability, PTGX's ROE is +0.12%, compared to REGN's ROE of +0.14%. Regarding short-term risk, PTGX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
PTGX vs MRNA Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, MRNA has a market cap of 75.4B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while MRNA trades at $190.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas MRNA's P/E ratio is -23.31. In terms of profitability, PTGX's ROE is +0.12%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, PTGX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
PTGX vs VRNA Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas VRNA's P/E ratio is -102.80. In terms of profitability, PTGX's ROE is +0.12%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, PTGX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
PTGX vs ARGX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ARGX has a market cap of 57.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ARGX trades at $919.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ARGX's P/E ratio is 33.14. In terms of profitability, PTGX's ROE is +0.12%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, PTGX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
PTGX vs RVMDW Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, RVMDW has a market cap of 45.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while RVMDW trades at $11.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas RVMDW's P/E ratio is -1.31. In terms of profitability, PTGX's ROE is +0.12%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, PTGX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
PTGX vs RVMD Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, RVMD has a market cap of 43.9B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while RVMD trades at $206.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas RVMD's P/E ratio is -23.43. In terms of profitability, PTGX's ROE is +0.12%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, PTGX is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
PTGX vs SGEN Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PTGX's ROE is +0.12%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PTGX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
PTGX vs ONC Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ONC has a market cap of 38.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ONC trades at $358.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ONC's P/E ratio is 63.04. In terms of profitability, PTGX's ROE is +0.12%, compared to ONC's ROE of +0.14%. Regarding short-term risk, PTGX is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
PTGX vs ALNY Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ALNY has a market cap of 29.4B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ALNY trades at $219.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ALNY's P/E ratio is 39.59. In terms of profitability, PTGX's ROE is +0.12%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, PTGX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
PTGX vs ROIV Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ROIV has a market cap of 25.8B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ROIV trades at $35.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ROIV's P/E ratio is -33.98. In terms of profitability, PTGX's ROE is +0.12%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, PTGX is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ROIV's competition here
BioNTech SE (NASDAQ: BNTX)
PTGX vs BNTX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while BNTX trades at $96.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas BNTX's P/E ratio is -12.57. In terms of profitability, PTGX's ROE is +0.12%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, PTGX is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
PTGX vs INSM Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, INSM has a market cap of 24.1B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while INSM trades at $111.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas INSM's P/E ratio is -27.04. In terms of profitability, PTGX's ROE is +0.12%, compared to INSM's ROE of -1.11%. Regarding short-term risk, PTGX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
PTGX vs INCY Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, INCY has a market cap of 23.4B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while INCY trades at $115.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas INCY's P/E ratio is 15.50. In terms of profitability, PTGX's ROE is +0.12%, compared to INCY's ROE of +0.30%. Regarding short-term risk, PTGX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
PTGX vs UTHR Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, UTHR has a market cap of 23B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while UTHR trades at $541.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas UTHR's P/E ratio is 19.38. In terms of profitability, PTGX's ROE is +0.12%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, PTGX is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
PTGX vs GMAB Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while GMAB trades at $34.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas GMAB's P/E ratio is 26.19. In terms of profitability, PTGX's ROE is +0.12%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, PTGX is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
PTGX vs BGNE Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PTGX's ROE is +0.12%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, PTGX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
PTGX vs DNA-WT Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PTGX's ROE is +0.12%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, PTGX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
PTGX vs JAZZ Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, JAZZ has a market cap of 14.8B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while JAZZ trades at $235.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas JAZZ's P/E ratio is 8.79. In terms of profitability, PTGX's ROE is +0.12%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, PTGX is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check JAZZ's competition here
Exelixis, Inc. (NASDAQ: EXEL)
PTGX vs EXEL Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while EXEL trades at $58.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas EXEL's P/E ratio is 16.68. In terms of profitability, PTGX's ROE is +0.12%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, PTGX is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
PTGX vs NBIX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, NBIX has a market cap of 14.4B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while NBIX trades at $143.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas NBIX's P/E ratio is 20.69. In terms of profitability, PTGX's ROE is +0.12%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, PTGX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
PTGX vs ASND Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ASND trades at $227.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ASND's P/E ratio is -94.16. In terms of profitability, PTGX's ROE is +0.12%, compared to ASND's ROE of +1.90%. Regarding short-term risk, PTGX is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ASND's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
PTGX vs SMMT Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, SMMT has a market cap of 13.4B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while SMMT trades at $16.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas SMMT's P/E ratio is -14.96. In terms of profitability, PTGX's ROE is +0.12%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, PTGX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check SMMT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
PTGX vs BBIO Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while BBIO trades at $67.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas BBIO's P/E ratio is -17.98. In terms of profitability, PTGX's ROE is +0.12%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, PTGX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check BBIO's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
PTGX vs HALO Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while HALO trades at $109.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas HALO's P/E ratio is 19.95. In terms of profitability, PTGX's ROE is +0.12%, compared to HALO's ROE of +1.81%. Regarding short-term risk, PTGX is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
PTGX vs KRTX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PTGX's ROE is +0.12%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PTGX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check KRTX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
PTGX vs TXG Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, TXG has a market cap of 11.9B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while TXG trades at $93.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas TXG's P/E ratio is -158.47. In terms of profitability, PTGX's ROE is +0.12%, compared to TXG's ROE of -0.09%. Regarding short-term risk, PTGX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check TXG's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
PTGX vs TWST Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, TWST has a market cap of 11.7B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while TWST trades at $188.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas TWST's P/E ratio is -84.99. In terms of profitability, PTGX's ROE is +0.12%, compared to TWST's ROE of -0.30%. Regarding short-term risk, PTGX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check TWST's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
PTGX vs MDGL Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while MDGL trades at $499.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas MDGL's P/E ratio is -39.02. In terms of profitability, PTGX's ROE is +0.12%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, PTGX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
PTGX vs TECH Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while TECH trades at $72.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas TECH's P/E ratio is 37.32. In terms of profitability, PTGX's ROE is +0.12%, compared to TECH's ROE of +0.09%. Regarding short-term risk, PTGX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
PTGX vs RNAM Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas RNAM's P/E ratio is -17.39. In terms of profitability, PTGX's ROE is +0.12%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, PTGX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
PTGX vs BMRN Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while BMRN trades at $57.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas BMRN's P/E ratio is 27.49. In terms of profitability, PTGX's ROE is +0.12%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, PTGX is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check BMRN's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
PTGX vs IBRX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, IBRX has a market cap of 10.8B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while IBRX trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas IBRX's P/E ratio is -10.60. In terms of profitability, PTGX's ROE is +0.12%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, PTGX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check IBRX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
PTGX vs RXDX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PTGX's ROE is +0.12%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PTGX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check RXDX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
PTGX vs KRYS Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, KRYS has a market cap of 9.5B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while KRYS trades at $322.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas KRYS's P/E ratio is 40.39. In terms of profitability, PTGX's ROE is +0.12%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, PTGX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check KRYS's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
PTGX vs AXSM Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, AXSM has a market cap of 9.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while AXSM trades at $179.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas AXSM's P/E ratio is -46.80. In terms of profitability, PTGX's ROE is +0.12%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, PTGX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check AXSM's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
PTGX vs NUVL Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas NUVL's P/E ratio is -21.79. In terms of profitability, PTGX's ROE is +0.12%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, PTGX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check NUVL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
PTGX vs ARWR Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ARWR has a market cap of 9B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ARWR trades at $64.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ARWR's P/E ratio is -28.53. In terms of profitability, PTGX's ROE is +0.12%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, PTGX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ARWR's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
PTGX vs CRNX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas CRNX's P/E ratio is -16.86. In terms of profitability, PTGX's ROE is +0.12%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, PTGX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CRNX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
PTGX vs KYMR Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, KYMR has a market cap of 8.8B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while KYMR trades at $107.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas KYMR's P/E ratio is -33.56. In terms of profitability, PTGX's ROE is +0.12%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, PTGX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check KYMR's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
PTGX vs IMGN Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PTGX's ROE is +0.12%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, PTGX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check IMGN's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
PTGX vs BPMC Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PTGX's ROE is +0.12%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, PTGX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
PTGX vs APGE Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas APGE's P/E ratio is -31.19. In terms of profitability, PTGX's ROE is +0.12%, compared to APGE's ROE of -0.30%. Regarding short-term risk, PTGX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check APGE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
PTGX vs TGTX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while TGTX trades at $54.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas TGTX's P/E ratio is 19.67. In terms of profitability, PTGX's ROE is +0.12%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, PTGX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check TGTX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
PTGX vs PRAX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, PRAX has a market cap of 8.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while PRAX trades at $295.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas PRAX's P/E ratio is -22.85. In terms of profitability, PTGX's ROE is +0.12%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, PTGX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
PTGX vs CERE Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas CERE's P/E ratio is -16.47. In terms of profitability, PTGX's ROE is +0.12%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PTGX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CERE's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
PTGX vs CYTK Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while CYTK trades at $65.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas CYTK's P/E ratio is -9.09. In terms of profitability, PTGX's ROE is +0.12%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, PTGX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check CYTK's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
PTGX vs PCVX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while PCVX trades at $56.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas PCVX's P/E ratio is -7.40. In terms of profitability, PTGX's ROE is +0.12%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, PTGX is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
PTGX vs SYRE Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, SYRE has a market cap of 8.1B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while SYRE trades at $93.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas SYRE's P/E ratio is -47.79. In terms of profitability, PTGX's ROE is +0.12%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, PTGX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check SYRE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
PTGX vs CAI Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, CAI has a market cap of 8B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while CAI trades at $28.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas CAI's P/E ratio is 79.52. In terms of profitability, PTGX's ROE is +0.12%, compared to CAI's ROE of +0.19%. Regarding short-term risk, PTGX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check CAI's competition here
Metsera, Inc. (NASDAQ: MTSR)
PTGX vs MTSR Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas MTSR's P/E ratio is -23.58. In terms of profitability, PTGX's ROE is +0.12%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, PTGX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
PTGX vs IONS Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, IONS has a market cap of 7.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while IONS trades at $43.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas IONS's P/E ratio is -13.31. In terms of profitability, PTGX's ROE is +0.12%, compared to IONS's ROE of -1.11%. Regarding short-term risk, PTGX is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check IONS's competition here
Immunovant, Inc. (NASDAQ: IMVT)
PTGX vs IMVT Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while IMVT trades at $33.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas IMVT's P/E ratio is -11.92. In terms of profitability, PTGX's ROE is +0.12%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, PTGX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check IMVT's competition here
Merus N.V. (NASDAQ: MRUS)
PTGX vs MRUS Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas MRUS's P/E ratio is -17.05. In terms of profitability, PTGX's ROE is +0.12%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, PTGX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check MRUS's competition here
Abivax S.A. (NASDAQ: ABVX)
PTGX vs ABVX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ABVX has a market cap of 6.8B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ABVX trades at $92.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ABVX's P/E ratio is -15.22. In terms of profitability, PTGX's ROE is +0.12%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, PTGX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ABVX's competition here
Arcellx, Inc. (NASDAQ: ACLX)
PTGX vs ACLX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ACLX's P/E ratio is -28.27. In terms of profitability, PTGX's ROE is +0.12%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, PTGX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
PTGX vs RETA Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas RETA's P/E ratio is -66.29. In terms of profitability, PTGX's ROE is +0.12%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PTGX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
PTGX vs BLTE Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while BLTE trades at $159.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas BLTE's P/E ratio is -85.33. In terms of profitability, PTGX's ROE is +0.12%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, PTGX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check BLTE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
PTGX vs RYTM Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while RYTM trades at $92.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas RYTM's P/E ratio is -29.85. In terms of profitability, PTGX's ROE is +0.12%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, PTGX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check RYTM's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
PTGX vs IOVA Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, IOVA has a market cap of 6.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while IOVA trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas IOVA's P/E ratio is -19.47. In terms of profitability, PTGX's ROE is +0.12%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, PTGX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check IOVA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
PTGX vs CNTA Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas CNTA's P/E ratio is -22.63. In terms of profitability, PTGX's ROE is +0.12%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, PTGX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
PTGX vs LGND Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while LGND trades at $302.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas LGND's P/E ratio is 33.26. In terms of profitability, PTGX's ROE is +0.12%, compared to LGND's ROE of +0.20%. Regarding short-term risk, PTGX is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check LGND's competition here
CG Oncology Inc. (NASDAQ: CGON)
PTGX vs CGON Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while CGON trades at $67.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas CGON's P/E ratio is -25.05. In terms of profitability, PTGX's ROE is +0.12%, compared to CGON's ROE of -0.25%. Regarding short-term risk, PTGX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check CGON's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
PTGX vs KOD Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, KOD has a market cap of 5.9B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while KOD trades at $94.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas KOD's P/E ratio is -22.65. In terms of profitability, PTGX's ROE is +0.12%, compared to KOD's ROE of -2.73%. Regarding short-term risk, PTGX is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check KOD's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
PTGX vs CDTX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas CDTX's P/E ratio is -19.77. In terms of profitability, PTGX's ROE is +0.12%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, PTGX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CDTX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
PTGX vs SRRK Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while SRRK trades at $46.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas SRRK's P/E ratio is -13.57. In terms of profitability, PTGX's ROE is +0.12%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, PTGX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check SRRK's competition here
Abcam plc (NASDAQ: ABCM)
PTGX vs ABCM Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PTGX's ROE is +0.12%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PTGX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
PTGX vs ISEE Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PTGX's ROE is +0.12%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PTGX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ISEE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
PTGX vs CRSP Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while CRSP trades at $55.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas CRSP's P/E ratio is -11.64. In terms of profitability, PTGX's ROE is +0.12%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, PTGX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check CRSP's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
PTGX vs COGT Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, COGT has a market cap of 5.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while COGT trades at $31.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas COGT's P/E ratio is -14.70. In terms of profitability, PTGX's ROE is +0.12%, compared to COGT's ROE of -0.73%. Regarding short-term risk, PTGX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
PTGX vs PTCT Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while PTCT trades at $63.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas PTCT's P/E ratio is -27.24. In terms of profitability, PTGX's ROE is +0.12%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, PTGX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check PTCT's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
PTGX vs TVTX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while TVTX trades at $56.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas TVTX's P/E ratio is -126.51. In terms of profitability, PTGX's ROE is +0.12%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, PTGX is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
PTGX vs APLS Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas APLS's P/E ratio is 38.35. In terms of profitability, PTGX's ROE is +0.12%, compared to APLS's ROE of +0.40%. Regarding short-term risk, PTGX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
PTGX vs ERAS Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ERAS trades at $14.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ERAS's P/E ratio is -15.85. In terms of profitability, PTGX's ROE is +0.12%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, PTGX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ERAS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
PTGX vs ORKA Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ORKA has a market cap of 5.1B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ORKA trades at $84.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ORKA's P/E ratio is -43.57. In terms of profitability, PTGX's ROE is +0.12%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, PTGX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ORKA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
PTGX vs MIRM Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, MIRM has a market cap of 5.1B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while MIRM trades at $82.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas MIRM's P/E ratio is -5.70. In terms of profitability, PTGX's ROE is +0.12%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, PTGX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check MIRM's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
PTGX vs DFTX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while DFTX trades at $37.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas DFTX's P/E ratio is N/A. In terms of profitability, PTGX's ROE is +0.12%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, PTGX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check DFTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
PTGX vs DNTH Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, DNTH has a market cap of 4.9B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while DNTH trades at $88.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas DNTH's P/E ratio is -21.26. In terms of profitability, PTGX's ROE is +0.12%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, PTGX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check DNTH's competition here
Veradermics, Incorporated (NYSE: MANE)
PTGX vs MANE Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while MANE trades at $116.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas MANE's P/E ratio is -37.17. In terms of profitability, PTGX's ROE is +0.12%, compared to MANE's ROE of -0.38%. Regarding short-term risk, PTGX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check MANE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
PTGX vs TERN Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas TERN's P/E ratio is -51.41. In terms of profitability, PTGX's ROE is +0.12%, compared to TERN's ROE of -0.20%. Regarding short-term risk, PTGX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check TERN's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
PTGX vs FOLD Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas FOLD's P/E ratio is -161.00. In terms of profitability, PTGX's ROE is +0.12%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, PTGX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check FOLD's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
PTGX vs ADPT Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ADPT trades at $28.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ADPT's P/E ratio is -69.15. In terms of profitability, PTGX's ROE is +0.12%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, PTGX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ADPT's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
PTGX vs AKRO Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas AKRO's P/E ratio is -14.57. In terms of profitability, PTGX's ROE is +0.12%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, PTGX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
PTGX vs ALPN Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PTGX's ROE is +0.12%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PTGX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ALPN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
PTGX vs EWTX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while EWTX trades at $41.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas EWTX's P/E ratio is -22.38. In terms of profitability, PTGX's ROE is +0.12%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, PTGX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check EWTX's competition here
Opthea Limited (NASDAQ: OPT)
PTGX vs OPT Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas OPT's P/E ratio is -1.52. In terms of profitability, PTGX's ROE is +0.12%, compared to OPT's ROE of +1.18%. Regarding short-term risk, PTGX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
PTGX vs PRTC Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas PRTC's P/E ratio is -3.78. In terms of profitability, PTGX's ROE is +0.12%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, PTGX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check PRTC's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
PTGX vs ABCL Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, ABCL has a market cap of 4.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while ABCL trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas ABCL's P/E ratio is -25.44. In terms of profitability, PTGX's ROE is +0.12%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, PTGX is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ABCL's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
PTGX vs RLAY Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while RLAY trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas RLAY's P/E ratio is -12.08. In terms of profitability, PTGX's ROE is +0.12%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, PTGX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
PTGX vs MRTX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PTGX's ROE is +0.12%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PTGX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check MRTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
PTGX vs CPRX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas CPRX's P/E ratio is 17.49. In terms of profitability, PTGX's ROE is +0.12%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, PTGX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CPRX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
PTGX vs TNGX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while TNGX trades at $23.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas TNGX's P/E ratio is -28.00. In terms of profitability, PTGX's ROE is +0.12%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, PTGX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check TNGX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
PTGX vs RYZB Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PTGX's ROE is +0.12%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PTGX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
PTGX vs CBAY Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PTGX's ROE is +0.12%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PTGX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CBAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
PTGX vs XENE Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, XENE has a market cap of 3.7B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while XENE trades at $38.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas XENE's P/E ratio is -8.09. In terms of profitability, PTGX's ROE is +0.12%, compared to XENE's ROE of -0.44%. Regarding short-term risk, PTGX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check XENE's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
PTGX vs TLX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while TLX trades at $10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas TLX's P/E ratio is 110.13. In terms of profitability, PTGX's ROE is +0.12%, compared to TLX's ROE of +0.07%. Regarding short-term risk, PTGX is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check TLX's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
PTGX vs IDYA Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, IDYA has a market cap of 3.6B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while IDYA trades at $37.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas IDYA's P/E ratio is -19.26. In terms of profitability, PTGX's ROE is +0.12%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, PTGX is less volatile compared to IDYA. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check IDYA's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
PTGX vs SWTX Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas SWTX's P/E ratio is -13.78. In terms of profitability, PTGX's ROE is +0.12%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, PTGX is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check SWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
PTGX vs PBLS Comparison October 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9B. In comparison, PBLS has a market cap of 3.5B. Regarding current trading prices, PTGX is priced at $140.06 on the NASDAQ, while PBLS trades at $30.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 135.98, whereas PBLS's P/E ratio is -16.11. In terms of profitability, PTGX's ROE is +0.12%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, PTGX is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check PBLS's competition here